DCM Advisors’s Ingevity NGVT Stock Holding History

DCM Advisors’s Portfolio NGVT Stock Details NGVT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q4	–	Sell	-5,241	Closed	-$374K	–	283
2021 Q3	$374K	Buy	+5,241	New	+$413K	0.14%	163
2021 Q2	–	Sell	-7,000	Closed	-$529K	–	261
2021 Q1	$529K	Hold	7,000	–	–	0.31%	108
2020 Q4	$530K	Buy	+7,000	New	+$456K	0.31%	98

Other funds holding NGVT

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Boston Partners Boston, Massachusetts $95.5B AUM 28.4% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

LSV Asset Management Chicago, Illinois $46.4B AUM 27.74% 1-Year Est. Return

AAM

Ardevora Asset Management London, United Kingdom $1.12B AUM 26.09% 1-Year Est. Return

Thrivent Financial for Lutherans Minneapolis, Minnesota $52.5B AUM 27.12% 1-Year Est. Return

MRCP

Maple Rock Capital Partners Toronto, Ontario, Canada $3.07B AUM 157.2% 1-Year Est. Return

BBCM

Broad Bay Capital Management New York $1.18B AUM 65.45% 1-Year Est. Return

DCM Advisors's NGVT Position: Q4 2021 in Review

DCM Advisors sold out of Ingevity (NGVT) in Q4 2021, closing a stake of 5,241 shares — an estimated $374K sold.

DCM Advisors first reported a position in NGVT in Q4 2020 and held it in 3 quarters. The position peaked at $530K in Q4 2020. 277 funds tracked by Wall St. Rank hold NGVT as of Q4 2021.

DCM Advisors reported no remaining Ingevity position as of Q4 2021 after selling out during the quarter.
DCM Advisors sold 5,241 Ingevity shares in Q4 2021, an estimated $374K.
DCM Advisors first reported a position in Ingevity in Q4 2020 and held it in 3 quarters.
DCM Advisors's Ingevity position peaked at $530K in Q4 2020.
277 funds tracked by Wall St. Rank held Ingevity as of Q4 2021.

Based on DCM Advisors's 13F filing for Q4 2021, filed 11 Feb 2022.